XSHG
600789
Market cap1.27bUSD
Oct 09, Last price
8.28CNY
1D
1.60%
1Q
19.48%
Jan 2017
10.84%
Name
Shandong Lukang Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Lukang Pharmaceutical Co.,Ltd., a Chinese enterprise, primarily focuses on the production and distribution of bio-pharmaceuticals and antibiotics. Their comprehensive product range features active pharmaceutical ingredients (APIs) and finished drug formulations for both human and veterinary use, alongside bio-pesticides, traditional herbal remedies, and amino acids. Beyond its core pharmaceutical operations, the company also engages in environmental management services, including wastewater treatment, odor control, and the maintenance of sewage facilities, as well as the manufacturing and sale of ecological protection materials. Established in 1966 as Jining Antibiotic Factory, the firm rebranded to its current name in October 1993. Headquartered in Jining, China, it maintains a global footprint, distributing its offerings to approximately 40 nations across Asia, Europe, Africa, and the United States.
Key people
Jing Zhang
Finance Director, Director · since 2024
Haifeng Cao
Deputy General Manager · since 2020
Defeng He
Deputy General Manager · since 2020
Zhigang Jin
Deputy General Manager · since 2024
Sujuan Yang
Deputy General Manager · since 2024
Baokun Jing
Secretary of the Board · since 2024
Kun Dong
General Manager, Director · since 2021
Chengtong Liu
Director · since 2024
Xin Peng
Chairman of the Board · since 2024
Director · since 2022
Wei Zhao
Director · since 2024
Zixin Deng
Independent Director · since 2021
Liliang Feng
Independent Director · since 2021
Independent Director · since 2021
Headquarters & legal address
山东省济宁高新区德源路88号
济宁市, SD 250000
CN
济宁市, SD 250000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||